Shopping Cart 0
Cart Subtotal
USD 0

Cevec Pharmaceuticals GmbH - Pharmaceuticals & Healthcare - Deals and Alliances Profile

Restricted to one authorized user; Open on 1 PC/ mobile / Tablet only.
Print Option: No
Copy Option: No
Download Option: No
Deliverable Format : PDF viewable on the website via username

Single User License
USD 250

Restricted to one authorized user; Open on 1 PC/ mobile / Tablet only.
Print Option: No
Copy Option: No
Download Option: No
Deliverable Format : PDF viewable on the website via username

Site License
USD 500

Multiple Users within the Company/ Enterprise
Print Option: Yes
Copy Option: Yes
Download Option: Yes
Deliverable Format : Excel, PDF viewable on the website via username

Corporate User License
USD 750

Details

Summary

Cevec Pharmaceuticals GmbH (Cevec) is a healthcare products company that provides production of biopharmaceuticals. The company produces recombinant glycoproteins and gene therapy vectors. It utilizes its CAP-Go technology developed expression system based on human cells, for the production of complexly glycosylated molecules including coagulation factors and other plasma proteins. Cevec's CAP-GT cell lines provide a novel platform for the industrial production of adenoviral vectors, AAV and lentiviral vectors, among others. The company offers CGMP manufacturing, cell line development, process development and contract manufacturing services, among others. Cevec is headquartered in Cologne, Germany.

Cevec Pharmaceuticals GmbH-Pharmaceuticals & Healthcare-Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals-Analysis of the company's financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.

- Deals by Year-Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.

- Deals by Type-Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.

- Deals by Region-Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.

- Deals by Sub-sector-Chart and table showing information on the number of deals and value reported by the company, by sub-sector.

- Major Deals-Information on the company's major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company's (major public companies) key financial metrics and ratios.

- Business Description-A brief description of the company's operations.

- Key Employees-A list of the key executives of the company.

- Important Locations and Subsidiaries-A list and contact details of key centers of operation and subsidiaries of the company.

- Key Competitors-A list of the key competitors of the company.

- Key Recent Developments-A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company's financial deals that enable you to understand the company's expansion/divestiture and fund requirements

- The profile enables you to analyze the company's financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company's business segments' expansion / divestiture strategy

- The profile presents deals from the company's core business segments' perspective to help you understand its corporate strategy.

Access elaborate information on the company's recent financial deals that enable you to understand the key deals which have shaped the company

- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company's key financial metrics and ratios.

Equip yourself with detailed information about the company's operations to identify potential customers and suppliers.

- The profile analyzes the company's business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company

- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research

- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

READ MORE

Table Of Content

Scope

Table of Contents

Table of Contents 3

List of Tables 4

List of Figures 4

Cevec Pharmaceuticals GmbH, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5

Cevec Pharmaceuticals GmbH, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6

Cevec Pharmaceuticals GmbH, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7

Cevec Pharmaceuticals GmbH, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8

Cevec Pharmaceuticals GmbH, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 9

Cevec Pharmaceuticals GmbH, Pharmaceuticals & Healthcare, Deal Details 11

Venture Financing 11

CEVEC Pharma Raises USD4.9 Million in Financing Round 11

Cevec Pharma Raises USD 3.6 Million In Extended Series C Financing 13

Partnerships 15

Cevec Pharma to Enter into Agreement with PlasmidFactory 15

Catalent Pharma Enters Into Co-Development Agreement With Cevec Pharma 16

Licensing Agreements 17

CSL Enters into Licensing Agreement with Cevec Pharma 17

Provecs Medical and medac Gesellschaft Enter into Licensing Agreement with CEVEC Pharma 18

NewLink Genetics Enters into Licensing Agreement with Cevec Pharma 19

BioLamina Enters into Licensing Agreement with Cevec Pharma 20

CEVEC Pharma Enters In to Licensing Agreement With Paragon Bioservices For Proprietary Human Cell Lines 21

Paragon Bioservices Enters into Licensing Agreement with CEVEC Pharma 22

Beckman Research Institute Enters into Licensing Agreement with CEVEC Pharma 23

CellGenix Enters into Licensing Agreement with Cevec Pharma 24

CEVEC Pharma Enters into Licensing Agreement with Genethon 25

CEVEC Pharma Enters into Licensing Agreement with Biotest 26

Vibalogics Enters into Licensing Agreement with Cevec Pharma for CAP Technology 27

Cevec Pharma Enters Into Licensing Agreement With Vakzine Projekt Management For CMV Dense Body Technology 28

Cevec Pharma Enters Into Licensing Agreement With Yuhan To Develop Therapeutic Proteins 29

Cevec Pharma Enters Into Licensing Agreement With CCS Cell Culture Service 30

Cevec Pharmaceuticals GmbH-Key Competitors 31

Cevec Pharmaceuticals GmbH-Key Employees 32

Cevec Pharmaceuticals GmbH-Locations And Subsidiaries 33

Head Office 33

Other Locations & Subsidiaries 33

Appendix 34

Methodology 34

About GlobalData 34

Contact Us 34

Disclaimer 34


List Of Figure

List of Figures

Cevec Pharmaceuticals GmbH, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2

Cevec Pharmaceuticals GmbH, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2

Cevec Pharmaceuticals GmbH, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2

Cevec Pharmaceuticals GmbH, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2

Cevec Pharmaceuticals GmbH, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5

Cevec Pharmaceuticals GmbH, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 6

Cevec Pharmaceuticals GmbH, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7

Cevec Pharmaceuticals GmbH, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8


List Of Table

List of Tables

Cevec Pharmaceuticals GmbH, Pharmaceuticals & Healthcare, Key Facts 2

Cevec Pharmaceuticals GmbH, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5

Cevec Pharmaceuticals GmbH, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6

Cevec Pharmaceuticals GmbH, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7

Cevec Pharmaceuticals GmbH, Deals By Therapy Area, 2012 to YTD 2018 8

Cevec Pharmaceuticals GmbH, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 9

CEVEC Pharma Raises USD4.9 Million in Financing Round 11

Cevec Pharma Raises USD 3.6 Million In Extended Series C Financing 13

Cevec Pharma to Enter into Agreement with PlasmidFactory 15

Catalent Pharma Enters Into Co-Development Agreement With Cevec Pharma 16

CSL Enters into Licensing Agreement with Cevec Pharma 17

Provecs Medical and medac Gesellschaft Enter into Licensing Agreement with CEVEC Pharma 18

NewLink Genetics Enters into Licensing Agreement with Cevec Pharma 19

BioLamina Enters into Licensing Agreement with Cevec Pharma 20

CEVEC Pharma Enters In to Licensing Agreement With Paragon Bioservices For Proprietary Human Cell Lines 21

Paragon Bioservices Enters into Licensing Agreement with CEVEC Pharma 22

Beckman Research Institute Enters into Licensing Agreement with CEVEC Pharma 23

CellGenix Enters into Licensing Agreement with Cevec Pharma 24

CEVEC Pharma Enters into Licensing Agreement with Genethon 25

CEVEC Pharma Enters into Licensing Agreement with Biotest 26

Vibalogics Enters into Licensing Agreement with Cevec Pharma for CAP Technology 27

Cevec Pharma Enters Into Licensing Agreement With Vakzine Projekt Management For CMV Dense Body Technology 28

Cevec Pharma Enters Into Licensing Agreement With Yuhan To Develop Therapeutic Proteins 29

Cevec Pharma Enters Into Licensing Agreement With CCS Cell Culture Service 30

Cevec Pharmaceuticals GmbH, Key Competitors 31

Cevec Pharmaceuticals GmbH, Key Employees 32

Cevec Pharmaceuticals GmbH, Subsidiaries 33

Licence Rights

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License: 
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

Section Purchase

To know more information on Purchase by Section, please send a mail to support@kenresearch.com

INQUIRE FOR COVID-19 IMPACT ANALYSIS

Products and Companies

Products

Cevec Pharmaceuticals GmbH, Deal Analysis, Mergers, Acquisitions, Asset Purchases, Asset Divestitures, Company Divestitures, Equity Offerings, Capital Raising, Debt Offerings, IPOs, Initial Public Offering, Private Placement, Private Investment In Public Equities, Secondary Offerings, Follow-On Offerings, Debt Private Placement, Public Debt Placement, Partnerships, Joint Venture, Licensing Agreements, Co-Marketing Agreements, Upfront Payment, Milestone Payment, Phases, Clinical Trials, Private Equity, Venture Capital, PE,VC, Asset Finance, Project Finance, Tax Equity Financing, Bond Financing, Lease Financing, New Build Financing, Deal Analysis By Market/sector, Deal Analysis By Geography, Deal Analysis By Deal Types, Key Employees, Locations And Subsidiaries, Competitors, Recent News, Company Overview, Key Facts, Deals By Year, Deal Details, Recent Developments, Significant Developments.

Company Profile

Company Profile Title

Summary

Cevec Pharmaceuticals GmbH (Cevec) is a healthcare products company that provides production of biopharmaceuticals. The company produces recombinant glycoproteins and gene therapy vectors. It utilizes its CAP-Go technology developed expression system based on human cells, for the production of complexly glycosylated molecules including coagulation factors and other plasma proteins. Cevec's CAP-GT cell lines provide a novel platform for the industrial production of adenoviral vectors, AAV and lentiviral vectors, among others. The company offers CGMP manufacturing, cell line development, process development and contract manufacturing services, among others. Cevec is headquartered in Cologne, Germany.

Cevec Pharmaceuticals GmbH-Pharmaceuticals & Healthcare-Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals-Analysis of the company's financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.

- Deals by Year-Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.

- Deals by Type-Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.

- Deals by Region-Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.

- Deals by Sub-sector-Chart and table showing information on the number of deals and value reported by the company, by sub-sector.

- Major Deals-Information on the company's major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company's (major public companies) key financial metrics and ratios.

- Business Description-A brief description of the company's operations.

- Key Employees-A list of the key executives of the company.

- Important Locations and Subsidiaries-A list and contact details of key centers of operation and subsidiaries of the company.

- Key Competitors-A list of the key competitors of the company.

- Key Recent Developments-A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company's financial deals that enable you to understand the company's expansion/divestiture and fund requirements

- The profile enables you to analyze the company's financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company's business segments' expansion / divestiture strategy

- The profile presents deals from the company's core business segments' perspective to help you understand its corporate strategy.

Access elaborate information on the company's recent financial deals that enable you to understand the key deals which have shaped the company

- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company's key financial metrics and ratios.

Equip yourself with detailed information about the company's operations to identify potential customers and suppliers.

- The profile analyzes the company's business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company

- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research

- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

READ MORE

Scope

Table of Contents

Table of Contents 3

List of Tables 4

List of Figures 4

Cevec Pharmaceuticals GmbH, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5

Cevec Pharmaceuticals GmbH, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6

Cevec Pharmaceuticals GmbH, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7

Cevec Pharmaceuticals GmbH, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8

Cevec Pharmaceuticals GmbH, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 9

Cevec Pharmaceuticals GmbH, Pharmaceuticals & Healthcare, Deal Details 11

Venture Financing 11

CEVEC Pharma Raises USD4.9 Million in Financing Round 11

Cevec Pharma Raises USD 3.6 Million In Extended Series C Financing 13

Partnerships 15

Cevec Pharma to Enter into Agreement with PlasmidFactory 15

Catalent Pharma Enters Into Co-Development Agreement With Cevec Pharma 16

Licensing Agreements 17

CSL Enters into Licensing Agreement with Cevec Pharma 17

Provecs Medical and medac Gesellschaft Enter into Licensing Agreement with CEVEC Pharma 18

NewLink Genetics Enters into Licensing Agreement with Cevec Pharma 19

BioLamina Enters into Licensing Agreement with Cevec Pharma 20

CEVEC Pharma Enters In to Licensing Agreement With Paragon Bioservices For Proprietary Human Cell Lines 21

Paragon Bioservices Enters into Licensing Agreement with CEVEC Pharma 22

Beckman Research Institute Enters into Licensing Agreement with CEVEC Pharma 23

CellGenix Enters into Licensing Agreement with Cevec Pharma 24

CEVEC Pharma Enters into Licensing Agreement with Genethon 25

CEVEC Pharma Enters into Licensing Agreement with Biotest 26

Vibalogics Enters into Licensing Agreement with Cevec Pharma for CAP Technology 27

Cevec Pharma Enters Into Licensing Agreement With Vakzine Projekt Management For CMV Dense Body Technology 28

Cevec Pharma Enters Into Licensing Agreement With Yuhan To Develop Therapeutic Proteins 29

Cevec Pharma Enters Into Licensing Agreement With CCS Cell Culture Service 30

Cevec Pharmaceuticals GmbH-Key Competitors 31

Cevec Pharmaceuticals GmbH-Key Employees 32

Cevec Pharmaceuticals GmbH-Locations And Subsidiaries 33

Head Office 33

Other Locations & Subsidiaries 33

Appendix 34

Methodology 34

About GlobalData 34

Contact Us 34

Disclaimer 34


List Of Figure

List of Figures

Cevec Pharmaceuticals GmbH, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2

Cevec Pharmaceuticals GmbH, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2

Cevec Pharmaceuticals GmbH, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2

Cevec Pharmaceuticals GmbH, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2

Cevec Pharmaceuticals GmbH, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5

Cevec Pharmaceuticals GmbH, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 6

Cevec Pharmaceuticals GmbH, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7

Cevec Pharmaceuticals GmbH, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8


List Of Table

List of Tables

Cevec Pharmaceuticals GmbH, Pharmaceuticals & Healthcare, Key Facts 2

Cevec Pharmaceuticals GmbH, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5

Cevec Pharmaceuticals GmbH, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6

Cevec Pharmaceuticals GmbH, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7

Cevec Pharmaceuticals GmbH, Deals By Therapy Area, 2012 to YTD 2018 8

Cevec Pharmaceuticals GmbH, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 9

CEVEC Pharma Raises USD4.9 Million in Financing Round 11

Cevec Pharma Raises USD 3.6 Million In Extended Series C Financing 13

Cevec Pharma to Enter into Agreement with PlasmidFactory 15

Catalent Pharma Enters Into Co-Development Agreement With Cevec Pharma 16

CSL Enters into Licensing Agreement with Cevec Pharma 17

Provecs Medical and medac Gesellschaft Enter into Licensing Agreement with CEVEC Pharma 18

NewLink Genetics Enters into Licensing Agreement with Cevec Pharma 19

BioLamina Enters into Licensing Agreement with Cevec Pharma 20

CEVEC Pharma Enters In to Licensing Agreement With Paragon Bioservices For Proprietary Human Cell Lines 21

Paragon Bioservices Enters into Licensing Agreement with CEVEC Pharma 22

Beckman Research Institute Enters into Licensing Agreement with CEVEC Pharma 23

CellGenix Enters into Licensing Agreement with Cevec Pharma 24

CEVEC Pharma Enters into Licensing Agreement with Genethon 25

CEVEC Pharma Enters into Licensing Agreement with Biotest 26

Vibalogics Enters into Licensing Agreement with Cevec Pharma for CAP Technology 27

Cevec Pharma Enters Into Licensing Agreement With Vakzine Projekt Management For CMV Dense Body Technology 28

Cevec Pharma Enters Into Licensing Agreement With Yuhan To Develop Therapeutic Proteins 29

Cevec Pharma Enters Into Licensing Agreement With CCS Cell Culture Service 30

Cevec Pharmaceuticals GmbH, Key Competitors 31

Cevec Pharmaceuticals GmbH, Key Employees 32

Cevec Pharmaceuticals GmbH, Subsidiaries 33

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License: 
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to support@kenresearch.com

INQUIRE FOR COVID-19 IMPACT ANALYSIS

Products

Cevec Pharmaceuticals GmbH, Deal Analysis, Mergers, Acquisitions, Asset Purchases, Asset Divestitures, Company Divestitures, Equity Offerings, Capital Raising, Debt Offerings, IPOs, Initial Public Offering, Private Placement, Private Investment In Public Equities, Secondary Offerings, Follow-On Offerings, Debt Private Placement, Public Debt Placement, Partnerships, Joint Venture, Licensing Agreements, Co-Marketing Agreements, Upfront Payment, Milestone Payment, Phases, Clinical Trials, Private Equity, Venture Capital, PE,VC, Asset Finance, Project Finance, Tax Equity Financing, Bond Financing, Lease Financing, New Build Financing, Deal Analysis By Market/sector, Deal Analysis By Geography, Deal Analysis By Deal Types, Key Employees, Locations And Subsidiaries, Competitors, Recent News, Company Overview, Key Facts, Deals By Year, Deal Details, Recent Developments, Significant Developments.